DPK Method Should Be Confirmed By Three-Arm BE Studies - FDA's Wilkin
Executive Summary
The dermatopharmacokinetics methodology being proposed for dermatological bioequivalence by FDA should first undergo validation through a three-way comparison of reference product to bioequivalent and bioinequivalent products, FDA Division of Dermatological and Dental Drug Products Director Jonathan Wilkin, MD, said.